Haemostatix
Catapult Venture Managers Limited has completed an investment into Nottingham based drug company Haemostatix Limited as part of a £.12million funding package from its existing investors.
The investment will enable Hameostatix to progress development of HaemoPlaxTM a synthetic platelet substitute desinged to replace platelets currently obtained from blood donation. Donor platelets, given by transfusion, assist in blood clotting and are currently used to treat cancer and surgical pationts at risk from severe bleeding.
Haemostatix also announced the appointment of a new chief executive, Dr Ben Nichols and a new independent non-executive director, Dr Grahaem Brown.